# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## **SCHEDULE 13G**

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)  $(\text{Amendment No. })^1$ 

Dynavax Technologies Corporation
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
268158102
(CUSIP Number)
June 3, 2009
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

<sup>&</sup>lt;sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

	-			
1	NAME OF REPO	RTING PERSON		
	Biotechnology V			
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) x	
	(b) o			
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	D 1			
NULL (DED OF	Delaware	COLE MOTING POLITER		
NUMBER OF SHARES	5	SOLE VOTING POWER		
BENEFICIALLY		0.1		
OWNED BY EACH	6	0 shares SHARED VOTING POWER		
REPORTING	0	SHARED VOTING POWER		
PERSON WITH		1,513,657		
	7	SOLE DISPOSITIVE POWER		
	,	SOLE DISTOSTITVE TOWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		1,513,657		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,513,657			
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	3.8%			
12	TYPE OF REPOR	TING PERSON		
	PN			

1	NAME OF REPORTING PERSON			
ļ				
2	Biotechnology Value Fund II, L.P.  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  (a)			
2	CHECK THE APP	(a) x		
3	SEC USE ONLY		(b) o	
ى ا	SEC USE OINLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	CITIZEINOIIII OI	TEMOL OF OROTHUE MICH		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING PERSON WITH				
PERSON WITH		1,042,000		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
	U	SHARED DISPOSITIVE FOWER		
		1,042,000		
9	AGGREGATE AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
_				
	1,042,000			
10	CHECK BOX IF T	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CL.	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	2.6%			
12	TYPE OF REPOR	TING PERSON		
	DAT			
1	l PN			

1	NAME OF REPORTING PERSON			
	BVF Investments, L.L.C.			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP			
	(b) o			
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY OWNED BY EACH		0 shares		
REPORTING	6	SHARED VOTING POWER		
PERSON WITH		2 550 000		
TEROOT WITH	7	3,758,000 SOLE DISPOSITIVE POWER		
	/	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		SHARED DISTOSITIVE FOWER		
		3,758,000		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
J	HOOKEDINE TIMOOTTI BETTETTOTTEB BT ETOTTEB OKTING TEROOTT			
	3,758,000			
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
	CHECK DON'T THE MOCKED THE MOON (3) ENCEDDED CERTAIN STRIKES			
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	9.4%			
12	TYPE OF REPORT	TING PERSON		
	00			

1	NAME OF REPORTING PERSON			
	Investment 10, L.			
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) x	
	(b) o			
3	SEC USE ONLY			
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION		
	Illinois			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY EACH REPORTING	6	SHARED VOTING POWER		
PERSON WITH				
PERSON WITH		406,000		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		406.000		
	A CODECATE AND	406,000		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	400,000			
10	406,000			
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	DED CENTE OF CLA	CC DEDDECEMEED DV AMOUNT IN DOM/(0)		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	1.00/			
12	1.0%	INC DEDCON		
12	TYPE OF REPORT	ING PERSON		
i <b>l</b>	00			

1	NAME OF REPO	RTING PERSON		
	BVF Partners L.			
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) x	
	(b) o			
3	SEC USE ONLY			
	C			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	D 1			
NULL (DED OF	Delaware	COLE MOTING POLITER		
NUMBER OF SHARES	5	SOLE VOTING POWER		
BENEFICIALLY		0 - h		
OWNED BY EACH	6	0 shares SHARED VOTING POWER		
REPORTING	0	SHARED VOTING POWER		
PERSON WITH		6,719,657		
	7	SOLE DISPOSITIVE POWER		
	,	SOLE DISTOSTITVE TOWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		SIMMLE DISTOSTITY DISTORY		
		6,719,657		
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	6,719,657			
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)		
	16.8%			
12	TYPE OF REPOR	TING PERSON		
	PN, IA			

1	NAME OF DEPOPEING DEPCON			
1	NAME OF REPORTING PERSON			
	DIVE			
	BVF Inc.			
2	CHECK THE APPR	COPRIATE BOX IF A MEMBER OF A GROUP	(a) x	
	(b) o			
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING				
PERSON WITH		6,719,657		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		6,719,657		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	6,719,657			
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
			_	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
11	I LICEIVI OI CLA	SO REFREDERIED DI THIOORI IN ROW (3)		
	16.8%			
12	TYPE OF REPORT	INC DEDSON		
14	I I PE OF KEPOKI.	ING FERSON		
	CO.			
II	CO			

1	NAME OF REPORTING PERSON			
	Mark N. Lampert			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x		(a) x	
3	SEC USE ONLY			
4	CITIZENSHIP OR PLACE OF ORGANIZATION			
	United States			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING				
PERSON WITH		6,719,657		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		6,719,657		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	6,719,657			
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
		• •		
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)		
		`,		
	16.8%			
12	TYPE OF REPORT	TING PERSON		
	IN			

#### CUSIP NO. 268158102

Item 1(a). Name of Issuer:

Dynavax Technologies Corporation, a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

2929 Seventh Street

Suite 100

Berkeley, California 94710-2753

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

BVF Investments, L.L.C. ("BVLLC") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

Investment 10, L.L.C. ("ILL10") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Illinois

BVF Partners L.P. ("Partners") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

BVF Inc. 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 900 North Michigan Avenue, Suite 1100 Chicago, Illinois 60611 Citizenship: United States Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.001 per share (the "Common Stock")

Item 2(e). CUSIP Number:

268158102

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

# /x/ Not applicable.

- (a) // Broker or dealer registered under Section 15 of the Exchange Act.
- (b) // Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) // Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) // Investment company registered under Section 8 of the Investment Company Act.
- (e) // An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
- (f) // An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
- (g) // A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
- (h) // A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) // A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
- (j) // Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

# Item 4. Ownership

(a) Amount beneficially owned:

As of the date hereof, (i) BVF may be deemed to own 1,513,657 shares of Common Stock, (ii) BVF2 may be deemed to own 1,042,000 shares of Common Stock, (iii) BVLLC may be deemed to own 3,758,000 shares of Common Stock and (iv) ILL10 may be deemed to own 406,000 shares of Common Stock.

Partners, as the general partner of BVF and BVF2, the manager of BVLLC and the investment adviser of ILL10, may be deemed to beneficially own the 6,719,657 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, BVLLC and ILL10.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 6,719,657 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 6,719,657 shares of Common Stock beneficially owned by BFV Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, BVLLC and ILL10 and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

## (b) Percent of class:

Based on 39,992,469 shares of Common Stock outstanding as of April 28, 2009, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 30, 2009. As of the date hereof, (i) BVF may be deemed to beneficially own approximately 3.8% of the outstanding shares of Common Stock, (ii) BVF2 may be deemed to own approximately 2.6% of the outstanding shares of Common Stock, (iii) BVLLC may be deemed to own approximately 9.4% of the outstanding shares of Common Stock, (iv) ILL10 may be deemed to beneficially own approximately 1.0% of the outstanding shares of Common Stock and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 16.8% of the outstanding shares of Common Stock.

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable

#### CUSIP NO. 268158102

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Pursuant to the operating agreement of BVLLC, Partners is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVLLC, in the shares of Common Stock and other securities of the issuer and to vote, exercise or convert and dispose of each security, and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, BVLLC and ILL10.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURE**

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 5, 2009

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INVESTMENTS, L.L.C.

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert President

/s/ Mark N. Lampert

MARK N. LAMPERT

#### JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G dated June 5, 2009 with respect to the shares of Common Stock of Dynavax Technologies Corporation and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: June 5, 2009

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INVESTMENTS, L.L.C.

By: BVF Partners L.P., its manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

INVESTMENT 10, L.L.C.

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT